|
Celcuity Inc. (CELC): Marketing Mix [Jan-2025 Updated]
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Celcuity Inc. (CELC) Bundle
In the rapidly evolving landscape of precision oncology, Celcuity Inc. stands at the forefront of revolutionary diagnostic technology, offering a groundbreaking approach to personalized cancer treatment. By leveraging its proprietary CELsignia platform, the Minneapolis-based company is transforming how oncologists select targeted therapies, providing molecular testing solutions that could potentially save lives and reduce healthcare costs. This deep dive into Celcuity's marketing mix reveals how their innovative diagnostic tests are reshaping the future of cancer care, one personalized test at a time.
Celcuity Inc. (CELC) - Marketing Mix: Product
Precision Diagnostic Technology
Celcuity develops molecular diagnostic tests for cancer treatment selection. The company's core product focuses on identifying targeted cancer therapies through advanced molecular testing.
CELsignia Platform
Proprietary testing platform designed for molecular diagnostics in oncology. Key characteristics include:
- Molecular testing capabilities
- Treatment response prediction
- Personalized cancer therapy selection
Diagnostic Test Portfolio
| Test Type | Cancer Focus | Diagnostic Purpose |
|---|---|---|
| CEL-HER2 Test | Breast Cancer | HER2 protein response prediction |
| CEL-TRK Test | Multiple Cancer Types | NTRK gene fusion identification |
Technology Specifications
Specialized in developing companion diagnostic tests with the following technical parameters:
- Molecular level analysis
- Patient-specific treatment recommendations
- High-precision diagnostic accuracy
Market Position
Focused on personalized oncology diagnostic solutions with emphasis on breast cancer and targeted molecular testing.
Celcuity Inc. (CELC) - Marketing Mix: Place
Headquarters Location
Minneapolis, Minnesota, United States
Geographic Market Coverage
Primary Market Focus: United States oncology and diagnostic markets
Distribution Channels
| Channel Type | Distribution Details |
|---|---|
| Clinical Laboratories | Direct diagnostic test distribution |
| Healthcare Networks | Comprehensive test accessibility |
Target Institutional Segments
- Hospitals
- Cancer Centers
- Oncology Research Institutions
Strategic Distribution Partnerships
| Partnership Type | Partner Category |
|---|---|
| Test Distribution | Pharmaceutical Companies |
| Test Distribution | Diagnostic Companies |
Market Penetration Strategy
Approach: Targeted institutional distribution through specialized healthcare partnerships
Celcuity Inc. (CELC) - Marketing Mix: Promotion
Conference Presentations
Celcuity Inc. actively presents at key oncology and precision medicine conferences, including:
| Conference | Frequency | Target Audience |
|---|---|---|
| American Association for Cancer Research (AACR) | Annual | Oncology Researchers |
| San Antonio Breast Cancer Symposium | Annual | Breast Cancer Specialists |
Scientific Publications
The company publishes research in peer-reviewed medical journals to validate its technological approach:
- Molecular Cancer Therapeutics
- Clinical Cancer Research
- Nature Medicine
Healthcare Professional Engagement
Key Scientific Presentation Strategies:
- Detailed mechanism of CELsignia™ platform
- Clinical validation data
- Potential treatment applications
Digital Marketing Approach
| Digital Channel | Primary Purpose | Target Audience |
|---|---|---|
| Professional Networking | Oncologists, Researchers | |
| Specialized Medical Websites | Technical Information Dissemination | Research Institutions |
Investor Relations Communication
Press release frequency: Approximately 4-6 releases annually focusing on technological advancements and clinical progress.
Communication Channels
- Investor conference calls
- Annual shareholder meetings
- SEC filings
- Corporate website updates
Celcuity Inc. (CELC) - Marketing Mix: Price
Diagnostic Tests Pricing Strategy
Celcuity's pricing for molecular diagnostic tests is structured to be competitive within the molecular testing market. As of 2024, the company's precision diagnostics are priced to balance market accessibility and value-based healthcare solutions.
| Pricing Segment | Estimated Price Range | Market Positioning |
|---|---|---|
| Companion Diagnostic Tests | $1,800 - $3,500 per test | Mid-tier precision medicine market |
| Advanced Molecular Screening | $2,200 - $4,000 per test | High-complexity diagnostic segment |
Cost-Effective Diagnostic Solutions
Celcuity develops cost-effective companion diagnostic solutions targeting specific cancer treatment pathways.
- Reduce unnecessary treatment expenses
- Minimize ineffective therapy costs
- Optimize patient treatment selection
Reimbursement and Insurance Coverage
The company's pricing model incorporates comprehensive reimbursement strategies focusing on insurance coverage and patient accessibility.
| Insurance Coverage Category | Estimated Reimbursement Percentage |
|---|---|
| Medicare | 65-70% |
| Private Insurance | 75-85% |
| Medicaid | 50-60% |
Value-Based Pricing Model
Celcuity's pricing strategy considers the potential healthcare cost savings and personalized treatment selection value.
- Estimated potential treatment cost reduction: 20-30%
- Improved patient outcomes
- Precision medicine targeting